Quest Diagnostics Company Profile (NYSE:DGX)

About Quest Diagnostics (NYSE:DGX)

Quest Diagnostics logoQuest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Health Care Services
  • Symbol: NYSE:DGX
  • CUSIP: 74834L10
  • Web:
  • Market Cap: $14.77 billion
  • Outstanding Shares: 136,825,000
Average Prices:
  • 50 Day Moving Avg: $104.21
  • 200 Day Moving Avg: $95.80
  • 52 Week Range: $75.20 - $108.61
  • Trailing P/E Ratio: 21.74
  • Foreward P/E Ratio: 18.40
  • P/E Growth: 2.38
Sales & Book Value:
  • Annual Revenue: $7.55 billion
  • Price / Sales: 1.96
  • Book Value: $33.80 per share
  • Price / Book: 3.19
  • Annual Dividend: $1.80
  • Dividend Yield: 1.7%
  • EBIDTA: $1.42 billion
  • Net Margins: 8.56%
  • Return on Equity: 14.61%
  • Return on Assets: 6.71%
  • Debt-to-Equity Ratio: 0.80%
  • Current Ratio: 1.56%
  • Quick Ratio: 1.48%
  • Average Volume: 878,713 shs.
  • Beta: 0.68
  • Short Ratio: 7.7

Frequently Asked Questions for Quest Diagnostics (NYSE:DGX)

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics announced a quarterly dividend on Tuesday, May 16th. Shareholders of record on Monday, July 10th will be given a dividend of $0.45 per share on Monday, July 24th. This represents a $1.80 annualized dividend and a dividend yield of 1.67%. The ex-dividend date of this dividend is Thursday, July 6th. View Quest Diagnostics' Dividend History.

How will Quest Diagnostics' stock buyback program work?

Quest Diagnostics declared that its Board of Directors has initiated a stock repurchase plan on Sunday, April 9th 2017, which allows the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy up to 7.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its shares are undervalued.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) issued its quarterly earnings data on Thursday, April, 20th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.18 by $0.16. The company earned $1.90 billion during the quarter, compared to analyst estimates of $1.87 billion. Quest Diagnostics had a net margin of 8.56% and a return on equity of 14.61%. The company's quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.12 EPS. View Quest Diagnostics' Earnings History.

When will Quest Diagnostics make its next earnings announcement?

Quest Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, July, 19th 2017. View Earnings Estimates for Quest Diagnostics.

What guidance has Quest Diagnostics issued on next quarter's earnings?

Quest Diagnostics updated its FY17 earnings guidance on Thursday, April, 20th. The company provided EPS guidance of $5.45-5.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.46. The company issued revenue guidance of $7.64-7.72 billion, compared to the consensus revenue estimate of $7.67 billion.

Where is Quest Diagnostics' stock going? Where will Quest Diagnostics' stock price be in 2017?

14 brokers have issued 1-year target prices for Quest Diagnostics' shares. Their forecasts range from $86.00 to $116.00. On average, they anticipate Quest Diagnostics' stock price to reach $106.29 in the next year. View Analyst Ratings for Quest Diagnostics.

What are analysts saying about Quest Diagnostics stock?

Here are some recent quotes from research analysts about Quest Diagnostics stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Quest Diagnostics’ is trading above the broader industry. The company's first-quarter earnings and revenues duly exceeded the Zacks Consensus Estimate. A bullish 2017 guidance also increased out confidence on the stock.  We are also optimistic about its focus on its recently narrowed two-point strategy. The company has witnessed significant growth through infectious disease testing, prescription drug monitoring and wellness business. In addition, alliance with hospitals and integrated delivery networks were the other growth drivers. Particularly, the company is positive about its agreement with PeaceHealth in the Pacific Northwest, which is expected to bolster growth, later in 2017. However, we are concerned about tough organic volume scenario. Although, the current numbers indicate a recovery, sustainability is a matter of question. This apart, price headwinds remain." (5/23/2017)
  • 2. Jefferies Group LLC analysts commented, "We are maintaining our Hold on DGX given our view that significant multiple expansion is unlikely from its current 10-year high P/E. That said, we do not expect its valuation to crack either given the company's stable fundamentals, the emerging opportunity with hospital labs, consistent dividend & buybacks, potential upside from US tax reform, and the composition of its shareholder base." (1/27/2017)

Who are some of Quest Diagnostics' key competitors?

Who owns Quest Diagnostics stock?

Quest Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.23%), Vanguard Group Inc. (9.87%), Macquarie Group Ltd. (6.11%), State Street Corp (5.06%), LSV Asset Management (2.30%) and Schroder Investment Management Group (1.60%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Everett Cunningham, Jeffrey M Leiden, Jenne K Britell, John B Ziegler and Michael E Prevoznik. View Institutional Ownership Trends for Quest Diagnostics.

Who sold Quest Diagnostics stock? Who is selling Quest Diagnostics stock?

Quest Diagnostics' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Crawford Investment Counsel Inc., Macquarie Group Ltd., LSV Asset Management, Parametric Portfolio Associates LLC, Westfield Capital Management Co. LP, Ariel Investments LLC and AQR Capital Management LLC. Company insiders that have sold Quest Diagnostics stock in the last year include Catherine T Doherty, Jeffrey M Leiden, Jenne K Britell, John B Ziegler and Michael E Prevoznik. View Insider Buying and Selling for Quest Diagnostics.

Who bought Quest Diagnostics stock? Who is buying Quest Diagnostics stock?

Quest Diagnostics' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Renaissance Technologies LLC, Janus Capital Management LLC, Seizert Capital Partners LLC, Bank of New York Mellon Corp and Clark Capital Management Group Inc.. View Insider Buying and Selling for Quest Diagnostics.

How do I buy Quest Diagnostics stock?

Shares of Quest Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Quest Diagnostics stock cost?

One share of Quest Diagnostics stock can currently be purchased for approximately $107.98.

Analyst Ratings

Consensus Ratings for Quest Diagnostics (NYSE:DGX) (?)
Ratings Breakdown: 2 Sell Ratings, 6 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Hold (Score: 2.36)
Consensus Price Target: $106.29 (1.56% downside)

Analysts' Ratings History for Quest Diagnostics (NYSE:DGX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017ArgusInitiated CoverageHold -> Hold$102.00LowView Rating Details
4/26/2017MizuhoBoost Price TargetBuy$110.00 -> $115.00LowView Rating Details
4/25/2017Canaccord GenuityBoost Price TargetBuy$102.00 -> $115.00LowView Rating Details
4/24/2017Evercore ISIReiterated RatingIn-Line$102.00 -> $104.50LowView Rating Details
4/23/2017Barclays PLCReiterated RatingEqual Weight$98.00 -> $100.00LowView Rating Details
4/23/2017Deutsche Bank AGReiterated RatingBuy$108.00 -> $115.00LowView Rating Details
4/21/2017Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$116.00LowView Rating Details
4/12/2017FBR & CoBoost Price TargetOutperform$103.00 -> $110.00LowView Rating Details
3/16/2017Bank of America CorpUpgradeUnderperform -> Neutral$85.00 -> $103.00MediumView Rating Details
3/16/2017Jefferies Group LLCReiterated RatingHold$96.00MediumView Rating Details
3/14/2017Goldman Sachs Group IncUpgradeBuy -> Conviction-Buy$113.00LowView Rating Details
9/9/2016Citigroup IncInitiated CoverageNeutral$86.00N/AView Rating Details
6/24/2016Jyske BankDowngradeNeutral -> SellN/AView Rating Details
6/7/2016Morgan StanleyReiterated RatingSellN/AView Rating Details
5/24/2016Credit Suisse Group AGReiterated RatingHoldN/AView Rating Details
5/22/2016KeyCorpReiterated RatingHoldN/AView Rating Details
5/16/2016Robert W. BairdReiterated RatingHoldN/AView Rating Details
4/22/2016Royal Bank of CanadaBoost Price TargetSector Perform$70.00 -> $76.00N/AView Rating Details
1/29/2016William BlairReiterated RatingHoldN/AView Rating Details
10/16/2015Wells Fargo & CoUpgradeUnderperform -> Market PerformN/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for Quest Diagnostics (NYSE:DGX)
Earnings by Quarter for Quest Diagnostics (NYSE:DGX)
Earnings History by Quarter for Quest Diagnostics (NYSE:DGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/20/2017Q1 2017$1.18$1.33$1.87 billion$1.90 billionViewN/AView Earnings Details
1/26/2017Q416$1.27$1.31$1.86 billion$1.86 billionViewListenView Earnings Details
10/20/2016Q316$1.35$1.37$1.53 billion$1.89 billionViewListenView Earnings Details
7/21/2016Q216$1.32$1.34$1.91 billion$1.91 billionViewListenView Earnings Details
4/21/2016Q116$1.12$1.12$1.82 billion$1.86 billionViewListenView Earnings Details
1/28/2016Q415$1.19$1.19$1.85 billion$1.85 billionViewListenView Earnings Details
10/22/2015Q315$1.26$1.28$1.89 billion$1.88 billionViewListenView Earnings Details
7/23/2015Q215$1.23$1.25$1.93 billion$1.93 billionViewListenView Earnings Details
4/23/2015Q115$1.04$1.05$1.85 billion$1.84 billionViewListenView Earnings Details
1/29/2015Q414$1.05$1.08$1.85 billion$1.90 billionViewListenView Earnings Details
10/23/2014Q314$1.08$1.10$1.87 billion$1.90 billionViewListenView Earnings Details
7/24/2014Q214$1.06$1.08$1.88 billion$1.90 billionViewN/AView Earnings Details
4/24/2014Q114$0.89$0.84$1.75 billion$1.75 billionViewListenView Earnings Details
1/30/2014Q413$0.93$0.97$1.74 billion$1.76 billionViewListenView Earnings Details
10/17/2013Q313$1.20$1.02$1.84 billion$1.79 billionViewListenView Earnings Details
7/18/2013Q2 2013$1.10$1.06$1.84 billion$1.82 billionViewListenView Earnings Details
4/17/2013Q1 2013$1.03$0.89$1.86 billion$1.80 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.02$1.01$1.83 billion$1.77 billionViewListenView Earnings Details
10/17/2012$1.18$1.18ViewN/AView Earnings Details
7/19/2012$1.17$1.17ViewN/AView Earnings Details
4/18/2012$1.01$1.07ViewN/AView Earnings Details
1/24/2012$1.06$1.23ViewN/AView Earnings Details
10/25/2011$1.11$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$1.01$1.00ViewN/AView Earnings Details
1/25/2011$0.91$0.98ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Quest Diagnostics (NYSE:DGX)
2017 EPS Consensus Estimate: $5.41
2018 EPS Consensus Estimate: $5.85
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$1.16$1.18$1.17
Q2 20175$1.39$1.43$1.42
Q3 20175$1.42$1.44$1.43
Q4 20175$1.36$1.43$1.39
Q1 20183$1.28$1.37$1.33
Q2 20183$1.50$1.53$1.52
Q3 20183$1.52$1.53$1.53
Q4 20183$1.46$1.49$1.47
(Data provided by Zacks Investment Research)


Current Dividend Information for Quest Diagnostics (NYSE:DGX)
Next Dividend:7/24/2017
Annual Dividend:$1.80
Dividend Yield:1.67%
Dividend Growth:9.60% (3 Year Average)
Payout Ratio:40.00% (Trailing 12 Months of Earnings)
32.37% (Based on This Year's Estimates)
30.66% (Based on Next Year's Estimates)
Track Record:5 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Quest Diagnostics (NYSE:DGX)

Dividend History by Quarter for Quest Diagnostics (NYSE:DGX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Quest Diagnostics (NYSE:DGX)
Insider Ownership Percentage: 1.50%
Institutional Ownership Percentage: 87.71%
Insider Trades by Quarter for Quest Diagnostics (NYSE:DGX)
Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)
Insider Trades by Quarter for Quest Diagnostics (NYSE:DGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/24/2017Jenne K BritellDirectorSell6,111$104.03$635,727.33View SEC Filing  
4/20/2017Michael E PrevoznikSVPSell29,513$100.00$2,951,300.00View SEC Filing  
3/16/2017Michael E PrevoznikSVPSell13,987$100.00$1,398,700.00View SEC Filing  
3/3/2017Catherine T DohertySVPSell7,162$98.28$703,881.36View SEC Filing  
2/27/2017Michael E PrevoznikSVPSell440$97.39$42,851.60View SEC Filing  
1/30/2017Catherine T DohertySVPSell80,000$90.58$7,246,400.00View SEC Filing  
8/19/2016Jenne K BritellDirectorSell4,000$84.76$339,040.00View SEC Filing  
8/10/2016Jenne K BritellDirectorSell4,000$85.20$340,800.00View SEC Filing  
8/3/2016Jeffrey M LeidenDirectorSell6,345$85.62$543,258.90View SEC Filing  
7/25/2016John B. ZieglerDirectorSell1,000$84.36$84,360.00View SEC Filing  
5/27/2016Catherine T DohertySVPSell47,334$77.27$3,657,498.18View SEC Filing  
5/12/2016Jenne K BritellDirectorSell8,000$75.68$605,440.00View SEC Filing  
5/9/2016Everett CunninghamSVPSell56,312$76.26$4,294,353.12View SEC Filing  
5/6/2016Everett CunninghamSVPSell50,447$76.00$3,833,972.00View SEC Filing  
4/25/2016Catherine T DohertySVPSell29,550$74.45$2,199,997.50View SEC Filing  
3/3/2015Michael E PrevoznikSVPSell3,261$71.16$232,052.76View SEC Filing  
2/11/2015Daniel StanzioneDirectorSell8,000$70.97$567,760.00View SEC Filing  
2/4/2015Gail R WilenskyDirectorSell8,000$72.34$578,720.00View SEC Filing  
2/3/2015John B ZieglerDirectorSell8,000$71.88$575,040.00View SEC Filing  
2/2/2015Thomas F BongiornoVPSell3,000$71.50$214,500.00View SEC Filing  
11/17/2014Jon R CohenSVPSell160,029$63.13$10,102,630.77View SEC Filing  
8/8/2014Catherine T DohertySVPSell25,000$60.12$1,503,000.00View SEC Filing  
8/4/2014Michael E PrevoznikSVPSell14,377$61.01$877,140.77View SEC Filing  
7/30/2014Jenne K BritellDirectorSell8,000$62.37$498,960.00View SEC Filing  
7/30/2014Michael E PrevoznikSVPSell16,384$62.51$1,024,163.84View SEC Filing  
7/29/2014John C Md BaldwinDirectorSell8,000$62.31$498,480.00View SEC Filing  
7/28/2014Thomas F BongiornoVPSell4,000$61.72$246,880.00View SEC Filing  
7/25/2014John B ZieglerDirectorSell8,000$61.90$495,200.00View SEC Filing  
5/22/2014John ZieglerDirectorSell2,973$57.65$171,393.45View SEC Filing  
5/7/2014Gary PfeifferDirectorSell10,000$55.95$559,500.00View SEC Filing  
5/5/2014Mark GuinanCFOBuy4,000$55.51$222,040.00View SEC Filing  
2/27/2014Jenne BritellDirectorSell10,000$52.74$527,400.00View SEC Filing  
2/19/2014Michael PrevoznikSVPSell2,860$52.26$149,463.60View SEC Filing  
2/18/2014Gail WilenskyDirectorSell30,000$52.93$1,587,900.00View SEC Filing  
2/6/2014Timothy MainDirectorBuy5,000$50.71$253,550.00View SEC Filing  
11/5/2013Thomas F BongiornoVPSell16,667$62.49$1,041,520.83View SEC Filing  
10/29/2013Thomas F BongiornoVPSell6,000$59.00$354,000.00View SEC Filing  
10/25/2013Gary M PfeifferDirectorSell2,000$58.10$116,200.00View SEC Filing  
9/17/2013Catherine DohertySVPSell43,334$62.00$2,686,708.00View SEC Filing  
8/14/2013Catherine DohertySVPSell33,000$59.85$1,975,050.00View SEC Filing  
8/12/2013John ZieglerDirectorSell1,953$59.45$116,105.85View SEC Filing  
8/8/2013Thomas BongiornoVPSell10,864$59.33$644,561.12View SEC Filing  
7/23/2013Jenne K BritellDirectorSell4,200$58.99$247,758.00View SEC Filing  
6/18/2013Michael E PrevoznikSVPSell126,667$62.64$7,934,420.88View SEC Filing  
5/22/2013John B ZieglerDirectorSell31,362$62.00$1,944,444.00View SEC Filing  
5/14/2013John C Md BaldwinDirectorSell1,214$59.41$72,123.74View SEC Filing  
4/11/2013John B ZieglerDirectorSell1,470$58.35$85,774.50View SEC Filing  
1/17/2013Gary M PfeifferDirectorSell10,000$60.00$600,000.00View SEC Filing  
10/3/2012Robert HagemannCFOSell46,667$64.00$2,986,688.00View SEC Filing  
8/7/2012Stephen H RusckowskiCEOBuy5,000$59.34$296,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Quest Diagnostics (NYSE:DGX)
Latest Headlines for Quest Diagnostics (NYSE:DGX)
DateHeadline logoQuest Diagnostics (DGX) PT Raised to $110 at BofA/Merrill Lynch; 'Lab Market Remains Healthy & M&A Pipeline Robust' - - May 26 at 5:17 PM logoQuest Diagnostics Hits a 52-Week High on Solid Prospects - Nasdaq - May 26 at 5:17 PM logoQuest Diagnostics Hits a 52-Week High on Solid Prospects - May 26 at 5:17 PM logoQuest Diagnostics Pushes Beyond Lab Tests With Treatment Prediction - May 26 at 5:17 PM logoZacks: Analysts Expect Quest Diagnostics Inc (DGX) to Announce $1.41 EPS - May 26 at 2:16 PM logoQuest Diagnostics Inc (DGX) Given Average Recommendation of "Hold" by Brokerages - May 23 at 3:02 PM logoQuest Diagnostics Inc (DGX) Raised to Buy at Zacks Investment Research - May 23 at 1:52 PM logoCould Quest Diagnostics Inc (DGX) Be The Last Remaining Undervalued Stock? - - May 23 at 12:28 PM logoQuest Diagnostics (DGX) Up 1.8% Since Earnings Report: Can It Continue? - May 23 at 12:28 PM logoQuest Diagnostics Inc (DGX) Stock Rating Lowered by Zacks Investment Research - May 22 at 3:14 PM logoCould Quest Diagnostics Inc (DGX) Be The Last Remaining Undervalued Stock? - May 22 at 9:17 AM logoRonna Sue Cohen Buys United Parcel Service Inc, Quest Diagnostics Inc, SPDR MidCap Trust Series ... - May 17 at 4:48 PM logo[$$] More American Workers Are Testing Positive for Drugs - May 16 at 9:47 PM logoThese states have the most workers using illegal drugs - May 16 at 4:44 PM logoQuest Diagnostics Inc (DGX) Declares Quarterly Dividend of $0.45 - May 16 at 1:02 PM logoIncreases in Illicit Drugs, Including Cocaine, Drive Workforce Drug Positivity to Highest Rate in 12 Years, Quest Diagnostics Analysis Finds - May 16 at 12:05 PM logoCraig Hallum Weighs in on Quest Diagnostics Inc's Q2 2017 Earnings (DGX) - May 16 at 8:02 AM logoQuest Diagnostics Inc (DGX) Research Coverage Started at Argus - May 13 at 12:32 AM logoQuest Diagnostics To Speak At The UBS Global Healthcare Conference - May 12 at 5:13 PM logoQuest Diagnostics Inc (DGX) Expected to Announce Quarterly Sales of $1.95 Billion - May 5 at 4:58 PM logoNiche Drug & Alcohol Testing Labs and Diagnostic Compliance Companies Adapt to Changing Legal Landscape - May 4 at 8:43 AM logoQuest Diagnostics Inc Expected to Earn FY2017 Earnings of $5.52 Per Share (DGX) - May 3 at 1:16 PM logoZacks: Analysts Anticipate Quest Diagnostics Inc (DGX) to Announce $1.41 EPS - May 3 at 10:04 AM logoQuest Diagnostics To Speak At The Deutsche Bank 42nd Annual Health Care Conference - May 2 at 7:31 PM logoQuest Diagnostics Inc Expected to Earn Q2 2017 Earnings of $1.41 Per Share (DGX) - May 2 at 8:42 AM logoQuest Diagnostics CIO Harnesses Insights And Technology For Better Healthcare Results - May 1 at 4:36 PM logoQuest Diagnostics CIO Lidia Fonseca Wins 2017 Forbes CIO Innovation Award - May 1 at 4:36 PM logoQuest Diagnostics and PeaceHealth Complete Transaction to Increase Access to Innovative, High-value Diagnostic Information Services in the Pacific Northwest - May 1 at 4:36 PM logoQuest Diagnostics (DGX) Earning Somewhat Positive Media Coverage, AlphaOne Reports - April 29 at 8:52 PM logoQuest Diagnostics Inc (DGX) Receives Consensus Rating of "Hold" from Brokerages - April 28 at 4:42 PM logoQuest Diagnostics Is Making Steady Progress in 5-Point Strategy - April 27 at 5:15 PM logoQuest Diagnostics Is Targeting 3 Focus Areas to Accelerate Growth - April 27 at 5:15 PM logoJ.P. Morgan Chase Commercial Mortgage Securities Corp. 2004-C3 -- Moody's Affirms Four Classes of JPMCC 2004-C3 - April 27 at 5:15 PM logoQuest Diagnostics (DGX) Earns News Impact Rating of 0.16 - April 26 at 11:04 PM logoQuest Diagnostics Inc (DGX) Director Jenne K. Britell Sells 6,111 Shares - April 26 at 8:40 PM logoETFs with exposure to Quest Diagnostics, Inc. : April 25, 2017 - April 25 at 4:27 PM logoQuest Diagnostics Could Get Greater Share of Laboratory Segment - April 25 at 11:52 AM logoHospital Health Systems Could Offer Growth for Quest Diagnostics - April 25 at 11:52 AM logoQuest Diagnostics’ Reference Testing, Hospital Outreach Segment - April 25 at 11:52 AM logoQuest Diagnostics Projects Run Rate Savings by End of 2017 - April 25 at 11:52 AM logoQuest Diagnostics Inc (DGX) to Post FY2017 Earnings of $5.57 Per Share, William Blair Forecasts - April 25 at 11:49 AM logoQuest Diagnostics, Inc. :DGX-US: Earnings Analysis: Q1, 2017 By the Numbers : April 24, 2017 - April 24 at 4:33 PM logoData Diagnostics Wins Gold at the 30th Annual Edison Awards - April 24 at 4:33 PM logoQuest Diagnostics: Expected to Have Robust Revenue Growth in 2017 - April 24 at 4:33 PM logoAnalyst Recommendations for Quest Diagnostics in 2017 - April 24 at 4:33 PM logoQuest Diagnostics Inc (DGX) Stock Rating Reaffirmed by Evercore ISI - April 24 at 2:12 PM logoQuest Diagnostics Inc Forecasted to Earn FY2021 Earnings of $7.15 Per Share (DGX) - April 24 at 12:28 PM logoFY2017 EPS Estimates for Quest Diagnostics Inc Raised by Analyst (DGX) - April 24 at 9:16 AM logoMasterCard, Intuitive Surgical and 2 More Could Rocket Higher This Spring--Here's Why … - April 24 at 8:58 AM logoQuest Diagnostics 50th Anniversary: Celebrating a Half Century of Life-Changing Results - April 24 at 8:58 AM



Quest Diagnostics (DGX) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff